• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Synaptogenix Inc.

    7/7/21 1:43:59 PM ET
    $SNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SNPX alert in real time by email
    SC 13G 1 ea143861-13galpha_synaptogen.htm SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. ___)

     

    SYNAPTOGENIX, INC.

     

    (Name of Issuer)

     

    COMMON STOCK, $0.0001 PAR VALUE

     

    (Title of Class of Securities)

     

    234652419

     

    (CUSIP Number)

     

    July 7, 2021

     

    (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(c)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    (Continued on following page(s)

     

    Page 1 of 5 Pages

     

     

     

     

     

     

    CUSIP No. 234652419   13G   Page 2 of 5 Pages

     

    1. NAMES OF REPORTING PERSON
      S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
       
      Alpha Capital Anstalt
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP:
      (a) ☐
      (b) ☐
    3.   SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Liechtenstein

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    5. SOLE VOTING POWER, – 331,282 Common Stock (1)
       
    6. SHARED VOTING POWER - None
       
    7. SOLE DISPOSITIVE POWER – 331,282 Common Stock (1)
       
    8. SHARED DISPOSITIVE POWER – None
       

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON -  
         
      331,282 Common Stock (1)  
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES  
         
      CERTAIN SHARES ☐
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9  
         
      5.49%  
    12. TYPE OF REPORTING PERSON  
         
      CO  

     

    (1)Based on 6,038,798 shares outstanding as of July 1, 2021 as reported in the Form 424B3 filed with the Securities and Exchange Commission on July 7, 2021.

     

     

     

     

    CUSIP No. 234652419   13G   Page 3 of 5 Pages

     

    ITEM 1 (a) NAME OF ISSUER: Synaptogenix, Inc.

     

    ITEM 1 (b) ADDRESS OF ISSUER’S PRINCIPAL EXECUTIVE OFFICES:

     

    1185 Avenue of the Americas, 3rd Floor, New York, NY 10036

     

    ITEM 2 (a) NAME OF PERSON FILING: Alpha Capital Anstalt

     

    ITEM 2 (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:

     

    Lettstrasse 32, FL-9490 Vaduz, Furstentums, Liechtenstein

     

    ITEM 2 (c) CITIZENSHIP: Liechtenstein

     

    ITEM 2 (d) TITLE OF CLASS OF SECURITIES: Common Stock, $0.0001 par value

     

    ITEM 2 (e) CUSIP NUMBER: 234652419

     

    ITEM 3 IF THIS STATEMENT IS FILED PURSUANT TO RULE 13D-1(B) OR 13D-2(B): Not applicable

     

    ITEM 4 OWNERSHIP

     

    (a) AMOUNT BENEFICIALLY OWNED: 331,282 Common Stock (1)

     

    (b) PERCENT OF CLASS: 5.49%

     

    (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS:

     

    (i) SOLE POWER TO VOTE OR DIRECT THE VOTE

     

    331,282 Common Stock (1)

     

    (ii) SHARED POWER TO VOTE OR DIRECT THE VOTE

     

    0 Shares

     

    (iii) SOLE POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    331,282 Common Stock (1)

     

    (iv) SHARED POWER TO DISPOSE OR TO DIRECT THE DISPOSITION OF

     

    0 Shares

     

     

     

     

    CUSIP No. 234652419   13G   Page 4 of 5 Pages

     

    ITEM 5 OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS

     

    Not applicable

     

    ITEM 6 OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON

     

    Not applicable

     

    ITEM 7 IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY

     

    Not applicable

     

    ITEM 8 IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP

     

    Not applicable

     

    ITEM 9 NOTICE OF DISSOLUTION OF GROUP

     

    Not applicable

     

     

     

     

    CUSIP No. 234652419   13G   Page 5 of 5 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      July 7, 2021
      (Date)
       
      /s/ Konrad Ackermann
      (Signature)
       
      Konrad Ackermann, Director
      (Name/Title)

     

     

     

    Get the next $SNPX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SNPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SNPX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

      Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch

      6/9/25 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

      $19.6 million in cash and cash equivalents as of September 30, 2024 Dramatically reduced cash burn rate expected NEW YORK, Dec. 20, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its Board of Directors has formed an independent Special Committee to explore strategic opportunities to create and enhance value for investors. Funding for such opportunities is supported by the Company's robust financial position including $19.6 million in cash as of September 30, 2024, with approximately 1.3 million common shares outstanding. "Synaptogenix

      12/20/24 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces $5.0 Million Financing

      NEW YORK, Sept. 11, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced today announced that it has entered into securities purchase agreements for a $5.0 million financing with existing investors involving the sale of 5,000 shares of its newly issued Series C convertible preferred stock ("preferred stock"), with a stated value of $1,000 per share, convertible into shares of its common stock in a registered public offering (the "Registered Offering") and a concurrent private placement (the "Private Placement" and collectively with the Registered

      9/11/24 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/6/24 10:16:19 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      2/8/23 6:05:21 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Synaptogenix Inc. (Amendment)

      SC 13G/A - Synaptogenix, Inc. (0001571934) (Subject)

      1/18/23 4:28:57 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Leadership Updates

    Live Leadership Updates

    See more
    • Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

      Singular focus on Bittensor (TAO), the leading AI token byadoption and market capitalization James Altucher to lead TAO token strategy initiatives Planned initial acquisition of $10 million in TAO equates to over two times the Company's current market capitalization; total acquisition target of $100 million NEW YORK, June 9, 2025 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company") today announced its launch of a differentiated cryptocurrency treasury strategy focused exclusively on the artificial intelligence (AI) crypto token "TAO," which is currently the top AI token by market capitalization and adoption. Well-known cryptocurrency and AI expert James Altuch

      6/9/25 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul Analytics

      Supports IP development for novel mushroom genetics and therapeutics for multiple indications NEW YORK, April 9, 2024 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it has increased its stake in psilocybin drug discovery company PsygaBio through its previously announced partnership with Cannasoul Analytics ("Cannasoul"). Synaptogenix acquired a 25% stake in Cannasoul during November of 2023 in support of research and development for psilocybin mushroom and cannabinoid-based therapeutics. Cannasoul is founded by the Technion Research & Develo

      4/9/24 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders

      Bryostatin-1 benefits in severe Alzheimer's disease patients were statistically significant with respect to placebo at p < 0.007 NEW YORK, Dec. 19, 2023 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel L. Alkon, M.D., was honored by the International Association of Biomedical Sciences for his presentation at the University of Southern California-sponsored IABS Forum-2023, a gathering of world-renowned neuroscientists and academics discussing "New Concepts for the Treatment of Neurodegenerative

      12/19/23 9:00:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Singer William S.

      4 - Synaptogenix, Inc. (0001571934) (Issuer)

      4/7/25 5:01:34 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Schechter Jonathan

      4 - Synaptogenix, Inc. (0001571934) (Issuer)

      4/7/25 5:00:58 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bernstein Bruce

      4 - Synaptogenix, Inc. (0001571934) (Issuer)

      4/7/25 5:00:15 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    Financials

    Live finance-specific insights

    See more
    • Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

      Conference Call to be held Tuesday, July 26th at 4:30pm ET NEW YORK, July 26, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced changes to its Scientific Advisory Board (SAB) in preparation for Phase 2 data from its Phase 2b clinical trial of Bryostatin-1 for patients suffering from advanced and moderately severe Alzheimer's disease (AD).  The SAB is comprised of industry and academic leaders in science and drug development and will be instrumental in the further development of the Company's regenerative therapies across AD, Fragile X syndrome,

      7/26/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Announces Corporate Update Conference Call

      NEW YORK, July 21, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX) ("the Company"), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced that it will hold a corporate update conference call for investors. The call will take place on Tuesday, July 26th at 4:30pm ET and will be hosted by the Company's Chief Executive Officer, Dr. Alan Tuchman, and its President and Chief Science Officer, Dr. Daniel Alkon. Drs. Tuchman and Alkon will also take live Q&A following their prepared remarks. The U.S. toll free dial-in for the conference call is (877) 407-8293, and the international dial-in number is 1-(201) 689-8349. Fo

      7/21/22 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

      NEW YORK, July 26, 2021 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), an emerging biopharmaceutical company focused on developing therapies for neurodegenerative diseases, today announced that its abstract for presentation at the Alzheimer's Association International Conference (AAIC) is now available entitled "Bryostatin Restores Cognitive Functions Above Baseline in Advanced Alzheimer's Disease (AD) Patients: A Regenerative Therapeutic Strategy." "Recent further analyses of pre-specified cohort results revealed clear evidence of Bryostatin therapeutic efficacy for advanced AD patients.  Analyses of treatment benefit, based on mean differences and as a function of successive dosing in

      7/26/21 9:15:00 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SNPX
    SEC Filings

    See more
    • Synaptogenix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Synaptogenix, Inc. (0001571934) (Filer)

      6/9/25 9:01:27 AM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Synaptogenix Inc.

      10-Q - Synaptogenix, Inc. (0001571934) (Filer)

      5/15/25 4:15:59 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Synaptogenix Inc.

      10-K - Synaptogenix, Inc. (0001571934) (Filer)

      3/27/25 5:23:10 PM ET
      $SNPX
      Biotechnology: Pharmaceutical Preparations
      Health Care